



## **AgiOS to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET**

January 26, 2026

CAMBRIDGE, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company will host a conference call and live webcast on Thursday, February 12, 2026, at 8:00 a.m. ET to report its fourth quarter and full year 2025 financial results and business highlights.

The live webcast will be accessible on the Investors section of the company's website ([www.agios.com](http://www.agios.com)) under the "Events & Presentations" tab. A replay of the webcast will be available on the company's website approximately two hours after the event.

### **About Agios: Fueled by Connections to Transform Rare Diseases™**

At Agios, our vision is to redefine the future of rare disease treatment. Fueled by connections, we build trusted partnerships with communities – collaborating to develop and deliver innovative medicines that have the potential to transform lives. With a foundation in hematology, we combine biological expertise with real-world insights to advance a growing pipeline of rare disease medicines that reflect the priorities of the people we serve. Agios is a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. To learn more, visit [www.agios.com](http://www.agios.com) and follow us on [LinkedIn](#) and [X](#).

#### **Contacts:**

##### **Investor Contact**

Morgan Sanford, Vice President, Investor Relations  
AgiOS Pharmaceuticals  
[morgan.sanford@agios.com](mailto:morgan.sanford@agios.com)

##### **Media Contact**

Eamonn Nolan, Senior Director, Corporate Communications  
AgiOS Pharmaceuticals  
[eamonn.nolan@agios.com](mailto:eamonn.nolan@agios.com)



Source: Agios Pharmaceuticals, Inc.